Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate.
BACKGROUND
Current limitations of interstitial photodynamic therapy (PDT) for treatment of prostate cancer include low drug selectivity after intravenous (i.v.) administration and incomplete ablation of glandular tissue. To overcome these limitations, intra-arterial (i.a.) injection of a photosensitizer was tested in a canine model.


METHODS
A lipophilic photosensitizer, SL052 formulated in liposomes or dissolved in dimethyl sulphoxide (DMSO), was injected into male dogs as an intravenous injection or intra-arterially via the prostate arteries. Optical fibers were inserted into the prostate 3h after i.v. or immediately following i.a. drug delivery. Laser light was delivered through the fibers in cycles controlled by a computer-driven switch. Drug concentration (fluorescence) and light transmission in prostate tissue were monitored during the course of PDT. Side effect profile and completeness of prostate gland ablation were the primary parameters compared among treatment groups. Control animals received drug-only or light-only treatment.


CONCLUSIONS
Thirteen dogs were treated by PDT mediated by i.a. injection of SL052 dissolved in DMSO and attained either complete ablation of prostatic glandular tissue or significant reduction of prostate volume compared with that of pre-PDT (p<0.0001). When compared to i.v. administration the i.a. route resulted in more complete photo-ablation. Associated side effect included acute urinary retention which resolved overtime. No incontinence was observed. With careful tailoring of PDT drug and light doses, interstitial PDT with i.a. injection of SL052-DMSO has the potential to provide effective treatment for prostate disease.
Xiao
Zhengwen
Z
Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
Owen
Richard J
RJ
Liu
Weiyang
W
Tulip
John
J
Brown
Kevin
K
Woo
Thomas
T
Moore
Ronald B
RB
D000818:Animals; D004285:Dogs; D007261:Infusions, Intra-Arterial; D008081:Liposomes / Q000008:administration & dosage; D008297:Male; D015394:Molecular Structure; D010569:Perylene / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011810:Quinoxalines / Q000008:administration & dosage / Q000737:chemistry* / Q000627:therapeutic use*
D008081:Liposomes; D017319:Photosensitizing Agents; D011810:Quinoxalines; C552679:SL 052; D010569:Perylene